Antibody Based Therapy in Coronary Artery Disease and Heart Failure
Journal Title: Heart Research – Open Journal - Year 2017, Vol 4, Issue 2
Abstract
The function of the immune system is to protect the host against disease. Antibodies are a key part of the adaptive response, recognising specific antigens and invading pathogens and marking them for destruction or blocking their activities. A mechanistic and molecular understanding of this process has allowed researchers to harness their natural function. They are now routinely used as a diagnostic tool in the clinic and in research to investigate pathological signalling. More recently, antibodies have been utilised for another application – therapy. Antibody based therapy is one of the newest and fastest growing with nearly 70 approved drugs to date and over 1000 in clinical trials. Investment from the pharmaceutical sector shows no signs of abating and this technology is now widely accepted for treating cancer, autoimmune and infectious diseases. In the context of the cardiovascular system however, antibody therapies are relatively limited. This review summarises the monoclonal antibodies approved for clinical use or currently in clinical trials for treating cardiovascular disorders. Presently, coronary artery disease, heart failure and transplant are the main indications, and monoclonal antibody therapies are discussed in the context of their specific applications.
Authors and Affiliations
Lorna R. Fiedler
Keywords
Related Articles
- EP ID EP558218
- DOI 10.17140/HROJ-4-140
- Views 139
- Downloads 0
Surgical Removal of Left Atrial Appendage Thrombus in a Patient with Acute Ischemic Stroke
Atrial fibrillation is a major risk factor for ischemic stroke. Left atrial appendage thrombus is responsible for the majority of cardioembolic stroke caused by atrial fibrillation. Left atrial appendage thrombus in a pa...
Cardiovascular Research: Past, Present and Future
Cardiovascular disease remains a leading cause of death and significant burden on healthcare systems worldwide. While interventional and preventative medicine has considerably changed the face of clinical practice, at th...
The Challenge of Dysglycemia and Coronary Heart Disease
The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally, and although there is a small increase in the incidence of type 1 diabetes mellitus, T2DM accounts for 95% of all individuals with diabetes.1 A h...
Saroglitazar: A New Drug to Treat Diabetic Hypertriglyceridemia
Dyslipidemia alone has been considered as one of the major modifiable risk factor for cardiovascular diseases (CVD) accounting for 50% of the 1st myocardial infarction (MI) cases worldwide.1 A recent epidemiological sur...
Non-Pharmacological Interventions in Refractory Angina
Refractory angina (RA) is defined by intractable cardiac chest pain despite standard medical therapy and revascularisation. Symptoms are associated with significant morbidity and compromised quality of life (QoL). Variou...